Given that MMP2 is the principal CTX receptor on the surface of tumor cells, the developed CTX-functionalized nanoplatform retains the flexibility to conjugate alternative diagnostic and therapeutic agents for different types of MMP2-overexpressing tumors. This evidence concerns the gene MMP2 and neoplasm.